Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ ...

I may have beaten this subject to death over the last month or so, but I cannot resist, and will write about it again.However ...

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.

Biotech stocks returned up to 36% in 2025, while longevity investing hit $8.5B in funding. Here’s the data individual ...

Biotech firms are gaining major traction in 2026 due to the global pandemic. Take a look at some of the key features of ...

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice ...

Currently, SXTC is trading at $6.60, up 456.59%. VERAXA Biotech develops next-generation antibody-based cancer therapies, including BiTAC T cell engagers and bispecific antibody-drug conjugates.The ...

The U.S. regulatory agency, currently headed by Acting Commissioner Kyle Diamantas, J.D., is also preparing for a change in ...

Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it, the ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...